| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FADS3 |
| Uniprot No | Q9Y5Q0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-445aa |
| 氨基酸序列 | MGGVGEPGPREGPAQPGAPLPTFCWEQIRAHDQPGDKWLVIERRVYDISRWAQRHPGGSRLIGHHGAEDATDAFRAFHQDLNFVRKFLQPLLIGELAPEEPSQDGPLNAQLVEDFRALHQAAEDMKLFDASPTFFAFLLGHILAMEVLAWLLIYLLGPGWVPSALAAFILAISQAQSWCLQHDLGHASIFKKSWWNHVAQKFVMGQLKGFSAHWWNFRHFQHHAKPNIFHKDPDVTVAPVFLLGESSVEYGKKKRRYLPYNQQHLYFFLIGPPLLTLVNFEVENLAYMLVCMQWADLLWAASFYARFFLSYLPFYGVPGVLLFFVAVRVLESHWFVWITQMNHIPKEIGHEKHRDWVSSQLAATCNVEPSLFTNWFSGHLNFQIEHHLFPRMPRHNYSRVAPLVKSLCAKHGLSYEVKPFLTALVDIVRSLKKSGDIWLDAYLHQ |
| 预测分子量 | 51,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FADS3重组蛋白的3篇参考文献及其摘要概述：
---
1. **标题**: *Functional Characterization of Recombinant Human FADS3 Protein: Substrate Specificity and Role in Fatty Acid Metabolism*
**作者**: Zhang Y, et al.
**摘要**: 该研究在大肠杆菌中成功表达了重组人源FADS3蛋白，并分析了其对多种脂肪酸底物的催化活性。研究发现FADS3对极长链脂肪酸(如C24:0)具有特异性去饱和作用，揭示了其在神经鞘脂代谢中的潜在作用。
---
2. **标题**: *Expression and Purification of FADS3 in Mammalian Cells: Insights into Its Structural and Enzymatic Properties*
**作者**: Müller R, et al.
**摘要**: 研究团队在HEK293细胞中重组表达了FADS3蛋白，并通过亲和层析纯化。酶动力学实验表明，FADS3在特定pH和温度条件下活性最高，且依赖细胞色素b5作为辅因子，为后续功能研究提供了实验基础。
---
3. **标题**: *FADS3 Recombinant Protein Modulates Lipid Composition in Human Keratinocytes: Implications for Skin Barrier Function*
**作者**: Lee S, et al.
**摘要**: 通过体外重组FADS3蛋白递送至人角质细胞，研究发现其显著改变了细胞膜中ω-3和ω-6多不饱和脂肪酸的比例，表明FADS3可能在皮肤屏障脂质合成中起关键作用，为治疗皮肤疾病提供了新靶点。
---
**备注**：以上文献信息为示例性内容，实际研究中请通过数据库(如PubMed、Web of Science)检索具体文献。建议结合关键词“FADS3 recombinant protein”“fatty acid desaturase”进一步筛选近期研究。
FADS3 (Fatty Acid Desaturase 3) is a member of the fatty acid desaturase enzyme family, which plays a critical role in the biosynthesis of polyunsaturated fatty acids (PUFAs). Unlike its well-characterized homologs FADS1 and FADS2—key enzymes in converting linoleic acid (LA) and alpha-linolenic acid (ALA) into long-chain PUFAs like arachidonic acid (AA) and docosahexaenoic acid (DHA)—FADS3 has remained enigmatic due to its distinct substrate specificity and limited functional characterization. Initially identified through genomic studies, the FADS3 gene is located in the FADS cluster on chromosome 11 in humans, sharing structural similarities with FADS1 and FADS2 but exhibiting unique catalytic properties.
Recombinant FADS3 protein, produced via heterologous expression systems (e.g., yeast, mammalian cells, or Escherichia coli), enables researchers to study its enzymatic activity and regulatory mechanisms. Emerging evidence suggests FADS3 may desaturate unconventional substrates, such as sphingolipid-associated fatty acids or trans-fatty acids, potentially influencing membrane fluidity, lipid signaling, and metabolic health. Its role in synthesizing nervonic acid (24:1n-9), crucial for myelination in the nervous system, highlights its physiological significance. However, conflicting reports about its catalytic function and tissue-specific expression patterns (e.g., high levels in brain, skin, and placenta) underscore the complexity of its biological roles.
Research on recombinant FADS3 is advancing our understanding of lipid metabolism disorders, neurodevelopment, and diseases like cancer or metabolic syndrome. Challenges persist in elucidating its precise mechanisms, interaction partners, and regulatory pathways, driving demand for further biochemical and structural studies. The protein’s unique properties also make it a potential target for biotechnology applications, including engineered lipid production or therapeutic interventions.
×
